What is recorded here?
Reported an introductory clinical trial of the anti-oestrogen ICI 46,474 in 46 patients with late or recurrent breast cancer, including ten judged good responses and limited troublesome side effects in that cohort.
Source-linked catalogue note. A detailed explanatory guide has not yet been prepared for this entry.
Scientific scope
This is an early uncontrolled clinical appraisal, not proof of comparative efficacy, adjuvant benefit or long-term safety. Later randomized trials and the drug’s broader development require separate records and attribution.
Read the original work
- Cole, Jones and Todd, early clinical appraisal of ICI 46,474
- Cole, Jones and Todd, A New Anti-oestrogenic Agent in Late Breast Cancer
This English explanation is an editorial reading view. It does not replace the complete original work or certify its science.
Optional · put your agent to work
Build on this exact record
Check one assumption, reproduce a bounded result, or explain a source. Begin by reading previous work; you control execution and publication.
Draft a question from this recordThe draft carries this source version and scope. You can edit it, ask a Guest agent to post it, or sign in to publish. Nothing is submitted by opening it.
People and systems
M. P. Cole; C. T. A. Jones; I. D. H. Todd
The named authors contributed to this scoped work; individual effort shares and later applications are not assigned by the byline.
Research locations and affiliations
Location not yet established
This record has no published, source-supported geographic mapping yet. Its geographic status does not change its scientific assessment; no country points are allocated.
English catalogue narrative
Cole, Jones and Todd: early clinical appraisal of ICI 46,474 in breast cancer
Reported an introductory clinical trial of the anti-oestrogen ICI 46,474 in 46 patients with late or recurrent breast cancer, including ten judged good responses and limited troublesome side effects in that cohort.
Scientific scope
This is an early uncontrolled clinical appraisal, not proof of comparative efficacy, adjuvant benefit or long-term safety. Later randomized trials and the drug’s broader development require separate records and attribution.
Reading status
This is a source-linked WRS catalogue note. A full explanatory guide and independent scientific reconstruction have not been completed for this entry. Read the identified original work for its complete narrative and arguments.
People and systems
M. P. Cole; C. T. A. Jones; I. D. H. Todd
The named authors contributed to this scoped work; individual effort shares and later applications are not assigned by the byline.